Monogram Orthopaedics Inc ( (MGRM) ) has released its Q2 earnings. Here is a breakdown of the information Monogram Orthopaedics Inc presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monogram Technologies Inc., an AI-driven robotics company focused on orthopedic surgery, is developing advanced surgical robots and related technologies to improve human health. The company recently announced a significant merger agreement with Zimmer Biomet Holdings, Inc., which will see Monogram become a wholly-owned subsidiary of Zimmer Biomet. Key financial highlights from the latest earnings report reveal a net loss of $8.6 million for the first half of 2025, with operating expenses totaling $6.4 million. Despite the losses, Monogram has secured FDA clearance for its mBôs™ TKA System, marking a critical milestone in its product development. Looking ahead, the merger with Zimmer Biomet is expected to provide Monogram with additional resources and support, positioning the company for potential growth and expansion in the orthopedic sector.